Newly discovered HIV genome modification may put a twist on vaccine and drug design

February 22, 2016

Researchers at University of California, San Diego School of Medicine have discovered that HIV infection of human immune cells triggers a massive increase in methylation, a chemical modification, to both human and viral RNA, aiding replication of the virus. The study, published February 22, 2016 in Nature Microbiology, identifies a new mechanism for controlling HIV replication and its interaction with the host immune system.

"We and other colleagues at pharmaceutical companies have worked over the years to develop drugs targeting HIV's genetic material, its RNA, but we never made it to the clinic," said senior author Tariq Rana, PhD, professor of pediatrics at UC San Diego School of Medicine. "Now we know why -- we were developing drugs using RNA targets that didn't have these modifications, when in reality the RNA was different."

In human cells, RNA is the genetic material that carries instructions from the DNA in a cell's nucleus out to the cytoplasm, where molecular machinery uses those instructions to build proteins. In contrast, HIV's entire genome is made up of RNA, not DNA. The virus hijacks its host's cellular machinery to translate its RNA to proteins.

Cells can chemically modify RNA to control or alter its function. One of these modifications, known as N6-methyladenosine (m6A), is common in humans and other organisms. But little was known about the role m6A plays in the human immune system, or in the interactions between our cells and invading pathogens, such as HIV.

In the study, Rana's team discovered m6A modifications in HIV RNA for the first time. They also examined m6A's effect on function in both HIV and human host RNA during infection of human immune cells.

"M6A had always been considered a steady modification of cellular RNA. Instead, it turned out to be extremely dynamic and highly responsive to external stimuli, such as viral infections" said Gianluigi Lichinchi, a graduate student in Rana's lab and first author of the study. "In the future, these findings could aid in improving the design and efficacy of HIV/AIDS vaccines."

One of the proteins encoded by HIV's RNA genome is Rev. After Rev proteins are built in the human host cell's cytoplasm, they move back into the nucleus, where they assemble at a particular point on HIV RNA called the Rev responsive element (RRE). There, Rev helps transport newly produced HIV RNA transcripts into the host cytoplasm. This is an essential step in viral replication.

The team determined that m6A modification of both human and viral RNA influences the interaction between the HIV Rev protein and the RNA RRE. When the researchers silenced the enzyme that removes m6A from RNA, HIV replication increased. Conversely, when they silenced the enzyme that adds m6A to RNA, HIV replication decreased -- a finding the researchers say could be exploited pharmacologically to combat the infection.

"The HIV field has missed this modification in physiological RNA structure and HIV genome for more than 30 years," Rana said. "I will not be surprised if other viruses with RNA genomes also exploit this m6A modification mechanism to evade immune surveillance and control their replication in human cells. These viruses include, for example, influenza, Hepatitis C, Ebola and Zika, just to name a few."
-end-
Study co-authors include Shang Gao, Vikas Bansal, UC San Diego; Yogesh Saletore, Weill Cornell Medical College; Gwendolyn Michelle Gonzalez, Yinsheng Wang, UC Riverside; and Christopher Mason, Weill Cornell Medical College and HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Feil Family Brain and Mind Research Institute.

This research was funded, in part, by the National Institutes of Health (grants EB020393, NS076465, AI43198, DA039562, DA030199), Sloan Foundation, Bert L. and N. Kuggie Vallee Foundation, Irma T. Hirschl and Monique Weill-Caulier Charitable Trusts, WorldQuant Foundation and STARR Consortium.

University of California - San Diego

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.